Exhibit 99.1

 

 

Sigma Labs Reports Third Quarter 2020 Financial Results

 

Management to Host Conference Call Today at 4:30 p.m. ET

 

SANTA FE, NM – October 22, 2020 - Sigma Labs, Inc. (NASDAQ:SGLB) (“Sigma Labs”), a leading developer of quality assurance software for the commercial 3D metal printing industry, reported its financial and operational results for the third quarter ended September 30, 2020.

 

Key Third Quarter 2020 and Subsequent Operational Highlights

 

●         Appointed Steve Immel to the position of Senior Director Business Development, North America;

 

oResponsible for engaging with 3D printer OEMS, additive manufacturers, academic institutions and research organizations to propel Sigma Labs PrintRite3D® in-process quality assurance solutions into production applications; and
oVeteran of the 3D printing industry having fulfilled leadership roles at 3D Systems, Materialise and Jabil Additive.

 

●         Extended OEM Agreement and completed certification process designating Additive Industries’ MetalFAB1 printers PrintRite3D® Ready:

 

oWill begin selling PrintRite3D® Melt-Pool Monitoring solution to new and existing users of MetalFAB1 3D printers; and
oReduced post-processing costs, less material waste, and faster part qualification for end users.

 

●         Awarded contract by Major Oil and Gas Services Company:

 

oTo begin production deployment of PrintRite3D® in-process quality assurance software, following a successful Rapid Test and Evaluation (RTE) program; and
oExtensive evaluation process involved running PrintRite3D® on an EOS single laser machine and an SLM dual laser machine.

 

         Awarded Contract From Coherent (NASDAQ: COHR) for New PrintRite3D Lite In-Process Quality Assurance System:

 

oLaunched its newest product, the PrintRite3D Lite In-Process Quality Assurance (IPQA) system;
oThe PrintRite3D Lite IPQA® system was designed and developed specifically to fulfill the need for melt pool quality monitoring for the small, compact, entry level machines being used in academia, R&D, dental, and industrial small lot production; and
oPrintRite3D Lite will be available for OEM licensing as well as third party retrofit installations.

 

●         Announced Strategic Alliance with IN4.OS for Factories of the Future:

 

oPartnered with IN4.OS to build Smart Factories of the Future to meet the demands of high technology sectors including defense, space, aerospace and life sciences;
oProvides flexibility in the manufacturing process to build custom mission critical parts on demand, with unprecedented complexity in times of shortages; and
   

 

 

oIN4.OS will be utilizing DMG MORI’s LASERTEC line of 3D metal printers, which have been designated as PrintRite3D® Ready.

 

●         Expanded market opportunity and announced PrintRite3D for Directed Energy Deposition (DED) additive processes:

oNew partnership with Northwestern University expands in-process quality assurance technology across a broad array of 3D printing processes;
oDED has been successfully applied in various industries, including aerospace, oil & gas, defense, marine and architecture; and
oCurrently engaged with additional commercial DED machine OEM partners to expand beta testing program.

 

Management Commentary

 

“The third quarter of 2020 was about execution and laying the foundation for a successful 2021 and we are very pleased to have made significant progress in each of the strategic initiatives that we established at the beginning of the year,” said Mark K. Ruport, President and Chief Executive Officer of Sigma Labs. “On the financial front, our balance sheet expanded during the third quarter by $3.5 million from the exercise of preferred warrants from our January 2020 private placement of convertible preferred stock and warrants. This, paired with a continued reduction in cash burn, has better positioned Sigma to weather any macro-economic storms that may arise over the coming months and extends our cash runway well into 2021.

 

“During the third quarter of 2020, we announced a contract with a major oil and gas services company, following a successful Rapid Test and Evaluation (RTE) program. The conversion from our RTE program to beginning production deployment is a testament to the traction our enabling technology is garnering in the additive manufacturing industry. This followed last quarter’s contract with Mitsubishi Heavy Industries, a global leader in engineering and manufacturing to implement PrintRite3D. These large global manufacturers adopting PrintRite3D as their quality assurance system of choice continues to validate Sigma’s technology and the need for a third party, standards-based system that can operate in a heterogeneous 3D printer environment.

 

“The strategic nature of our agreements with Additive Industries and Coherent combined with our partnership with DMG MORI cannot be overstated. Each provides leverage to our business model, increases our global reach, expands our footprint in the industry and adds more validation to our technology.

 

“We also expanded our addressable market opportunity with Printrite3D Lite and PrintRite3D DED. We are excited to have Coherent as our initial customer for PrintRite3D Lite and to work with Northwestern University, our initial customer for PrintRite3D DED. Each market offers significant opportunities for revenue growth while extending our IPQA technology across different processes on the manufacturing floor,” continued Ruport.

 

“As we look into 2021, Sigma Labs will remain laser-focused on building leverage into our business model and expanding our reach and footprint in the industry. Our priorities are: driving multi-unit sales of PrintRite3D Production Series by end users that have validated our technology through the @Sigma RTE program; forming new strategic alliances and OEM contracts with both additive manufacturing hardware and software companies that provide sales leverage and market validation; and continued success with R&D organizations and universities. We look forward to sharing more on our developing story at upcoming investor conferences and virtual roadshows in the fourth quarter of 2020,” concluded Ruport.

 

   

 

 

Third Quarter 2020 Financial Results

 

Revenue for the third quarter of 2020 totaled $0.25 million. This compares to revenues of $0.17 million for the third quarter of 2019. The increase in revenue was due to increased PrintRite3D® unit sales, including the first sale of a PrintRite3D Lite® unit during the quarter.

 

Gross profit for the third quarter of 2020 was $0.15 million as compared to negative $8 thousand in the third quarter of 2019.

 

Total operating expenses for the third quarter of 2020 were $1.4 million as compared to total operating expenses of $1.6 million for the same period in 2019.

 

Cash used in operating activities for the three months ended September 30, 2020 totaled $1.2 million compared to $1.8 million in the third quarter of 2019, a decrease of $0.6 million. Cash used in operating activities for the nine months ended September 30, 2020 totaled $3.7 million compared to $4.5 million for the first nine months of 2019. The decrease in year-to-date cash used in 2020 versus 2019 was driven primarily by a $967,161 decrease in net loss.

 

Net loss for the third quarter of 2020 was $1.2 million, or $(0.42) per share, as compared to a net loss of $1.6 million, or $(1.20) per share, in the third quarter of 2019.

 

Cash totaled $4.5 million at September 30, 2020, as compared to $2.5 million at June 30, 2020 and $1.1 million at September 30, 2019. The increase in cash during the period was a result of warrant exercises from our January 2020 private placement of convertible preferred stock and warrants.

 

Third Quarter 2020 Results Conference Call

 

Sigma Labs President and CEO Mark Ruport and CFO Frank Orzechowski will host the conference call, followed by a question and answer period.

 

To access the call, please use the following information:

 

Date: Thursday, October 22, 2020
Time: 4:30 p.m. Eastern time, 1:30 p.m. Pacific time
Toll-free dial-in number: 1-877-407-9039
International dial-in number: 1-201-689-8470
Conference ID: 13711743

 

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.

 

The conference call will be broadcast live and available for replay at http://public.viavid.com/index.php?id=141888 and via the investor relations section of the Company’s website at www.sigmalabsinc.com.

 

A replay of the conference call will be available after 7:30 p.m. Eastern time through November 5, 2020.

 

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 13711743

 

   

 

 

About Sigma Labs

 

Sigma Labs Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D® brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D® for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.sigmalabsinc.com.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors, including, but not limited to, the uncertain effect of the COVID-19 pandemic on the Sigma Labs’ business, results of operations and financial condition, which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K (including but not limited to the discussion under “Risk Factors” therein) filed with the SEC on March 24, 2020 and which may be viewed at www.sec.gov.

 

Investor Contact:

 

Chris Tyson

Managing Director

MZ Group - MZ North America

949-491-8235

SGLB@mzgroup.us

www.mzgroup.us

 

Company Contact:

 

Steven Gersten

Sigma Internal IR

813-334-9745

investors@sigmalabsinc.com

 

   

 

 

Sigma Labs, Inc.

Condensed Balance Sheets

(Unaudited)

 

   September 30, 2020   December 31, 2019 
         
ASSETS          
Current Assets:          
Cash  $4,510,548   $86,919 
Accounts Receivable, net   485,067    55,540 
Inventory   574,540    598,718 
Prepaid Assets   144,058    199,727 
Total Current Assets   5,714,212    940,904 
           
Other Assets:          
Property and Equipment, net   154,204    128,723 
Intangible Assets, net   707,663    569,341 
Investment in Joint Venture   -    500 
Long-Term Prepaid Asset   52,000    52,000 
Total Other Assets   913,867    750,564 
           
TOTAL ASSETS  $6,628,079   $1,691,468 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current Liabilities:          
Accounts Payable  $182,123   $727,114 
Notes Payable   -    50,000 
Deferred Revenue   92,841    139,447 
Accrued Expenses   230,680    122,658 
Total Current Liabilities   505,644    1,039,219 
           
Long-Term Liabilities:          
CARES Act Deferred Payroll Tax Liability   53,545    - 
Total Long-Term Liabilities   53,545    - 
           
TOTAL LIABILITIES   559,189    1,039,219 
           
Stockholders’ Equity          
Preferred Stock, $0.001 par; 10,000,000 shares authorized; 583 and 0 issued and outstanding, respectively   1    - 
Common Stock, $0.001 par; 12,000,000 shares authorized; 5,833,245 and 1,403,759 issued and outstanding, respectively   5,833    1,404 
Additional Paid-In Capital   37,614,357    26,746,439 
Accumulated Deficit   (31,551,301)   (26,095,594)
Total Stockholders’ Equity   6,068,890    652,249 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $6,628,079   $1,691,468 

 

   

 

 

Sigma Labs, Inc.

Condensed Statements of Operations

(Unaudited)

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2020   2019   2020   2019 
                 
REVENUES  $248,526   $171,003   $637,944   $269,035 
                     
COST OF REVENUE   97,785    178,760    400,172    335,939 
                     
GROSS PROFIT (LOSS)   150,741    (7,757)   237,772    (66,904)
                     
OPERATING EXPENSES:                    
Salaries & Benefits   657,889    644,800    1,915,381    1,738,716 
Stock-Based Compensation   58,219    79,202    483,208    403,768 
Operating R&D Costs   79,673    212,230    245,008    476,346 
Investor & Public Relations   272,964    269,130    682,518    734,237 
Legal & Professional Service Fees   100,144    116,221    530,660    519,710 
Office Expenses   84,357    186,430    310,947    536,608 
Depreciation & Amortization   50,167    52,636    86,150    150,222 
Other Operating Expenses   59,100    40,265    194,836    117,470 
Total Operating Expenses   1,362,513    1,600,914    4,448,708    4,677,077 
                     
LOSS FROM OPERATIONS   (1,211,772)   (1,608,671)   (4,210,936)   (4,743,981)
                     
OTHER INCOME (EXPENSE)                    
Interest Income   77    4,812    959    17,610 
State Incentives   -    -    151,657    51,877 
Exchange Rate Gain (Loss)   (252)   (549)   (1,674)   (3,259)
Interest Expense   (6,066)   (2,149)   (12,741)   (6,407)
Loss on Dissolution of Joint Venture   -    -    (201)   - 
    Other Income   -    5,763    361,700    5,763 
Total Other Income (Expense)   (6,241)   7,877    499,700    65,584 
                     
LOSS BEFORE PROVISION FOR INCOME TAXES   (1,218,013)   (1,600,794)   (3,711,236)   (4,678,397)
                     
Provision for income Taxes   -    -    -    - 
                     
Net Loss  $(1,218,013)  $(1,600,794)  $(3,711,236)  $(4,678,397)
                     
Preferred Dividends   (737,344)   -    (1,744,471)   - 
                     
Net Loss Applicable to Common Stockholders  $(1,955,357)  $(1,600,794)  $(5,455,707)  $(4,678,397)
                     
Net Loss per Common Share – Basic and Diluted  $(0.42)  $(1.20)  $(1.74)  $(4.30)
                     
Weighted Average Number of Shares Outstanding – Basic and Diluted   4,675,749    1,285,160    3,137,459    1,099,627 

 

   

 

 

Sigma Labs, Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

   Nine Months Ended 
   September 30, 2020   September 30, 2019 
OPERATING ACTIVITIES          
Net Loss  $(3,711,236)  $(4,678,397)
Adjustments to reconcile Net Loss to Net Cash used in operating activities:          
Noncash Expenses:          
Depreciation and Amortization   86,150    150,222 
Stock Based Compensation   483,208    403,768 
Securities Issued for Third Party Services   113,843    17,110 
Securities Issued to Directors for Services   131,150    225,000 
           
Change in assets and liabilities:          
Accounts Receivable   (429,527)   (42,403)
Interest Receivable   -    1,391 
Inventory   24,178    (472,501)
Prepaid Assets   55,669    (179,191)
Accounts Payable   (544,991)   205,571 
Deferred Revenue   (46,606)   48,345 
Accrued Expenses   108,022    (177,494)
NET CASH USED IN OPERATING ACTIVITIES   (3,730,140)   (4,498,579)
           
INVESTING ACTIVITIES          
Purchase of Property and Equipment   (88,074)   (33,487)
Purchase of Intangible Assets   (161,878)   (157,922)
Payment Received from Notes Receivable   -    120,522 
Dissolution of Joint Venture   500    - 
NET CASH USED IN INVESTING ACTIVITIES   (249,452)   (70,887)
           
FINANCING ACTIVITIES          
Gross Proceeds from Public and Private Issuances of Securities   3,600,000    4,981,220 
Less Offering Costs   (820,224)   (655,954)
Payment of Note Payable   (50,000)   - 
Proceeds from Exercise of Warrants   5,619,900    75,848 
Deferral of Payroll Taxes under the CARES Act   53,545    - 
NET CASH PROVIDED BY FINANCING ACTIVITIES   8,403,221    4,401,114 
           
NET CHANGE IN CASH FOR PERIOD   4,423,629    (168,352)
           
CASH AT BEGINNING OF PERIOD   86,919    1,279,782 
           
CASH AT END OF PERIOD  $4,510,548   $1,111,430 
           
Supplemental Disclosures:          
Noncash investing and financing activities disclosure:          
           
Issuance of Common Shares for Conversion of Preferred Shares and Preferred Dividends  $7,460,121   $- 
Issuance of Securities for Services  $244,993   $245,111 
Disclosure of cash paid for:          
Interest  $12,741   $2,514 
Income Taxes  $-   $-